[生物书合集].Advances.in.Clinical.TBiostatisti

生& - Bayesian Methods for Cancer Phase I Clinical Trials 25 trial paradigm(ASCO 1997 Such design alternatives often referred to

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
trial paradigm (ASCO, 1997). Such design alternatives, often referred to as accelerated titration designs (Simon et al., 1997), begin with an aggressive, rapid initial escalation of dose and mandate switching to a more con- servative approach when some prespecified target is achieved. The switch- ingrule isusuallybasedonadefinedincidenceofsome levelof toxicity (e.g., the second hematologic toxicity of grade 2 or higher), or a pharmacologic endpoint such as 40% of the AUC at the mouse LD 10 . In the context of Bayesian phase I designs, Moller (1995) and Goodman et al. (1995) proposed two-stage phase I dose escalation schemes wherein implementa- tion of a Bayesian design was preceded by a rapid ad hoc dose escalation phase.There may beconsiderableadvantagein adoptingthetwo-stage trial design since the first stage may not only reduce the incidence of non- therapeutic dose assignments, but would also provide meaningful prior information on which to base the Bayesian design of the second stage. 3.4.
Background image of page 1
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 06/13/2011 for the course PHYSICS 101 taught by Professor Shu during the Spring '11 term at FIU.

Ask a homework question - tutors are online